A citation-based method for searching scientific literature

S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
Times Cited: 89







List of co-cited articles
795 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
66
60


Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
61
42

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
27

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
73
31


Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Johan Farngren, Margaretha Persson, Anja Schweizer, James E Foley, Bo Ahrén. J Clin Endocrinol Metab 2012
63
30

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
20

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
271
19


Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
17

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
121
16

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
134
16


The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
36
38



Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
149
15

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
102
15


Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing,[...]. PLoS One 2008
56
23

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
185
14

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
120
14

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
761
14

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
190
14


Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
13

Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
Ottavio Giampietro, Chiara Giampietro, Luca Della Bartola, Maria Chiara Masoni, Elena Matteucci. Drug Des Devel Ther 2013
22
54

C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Odd Erik Johansen, Bernhard O Boehm, Valdemar Grill, Peter A Torjesen, Sudipta Bhattacharya, Sanjay Patel, Kristiane Wetzel, Hans-Juergen Woerle. Diabetes Care 2014
42
28

The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
60
18

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
412
12


Effect of pioglitazone therapy in lean type 1 diabetes mellitus.
R Bhat, A Bhansali, S Bhadada, R Sialy. Diabetes Res Clin Pract 2007
30
33

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz, Orville Kolterman. Diabetes Care 2006
99
11


Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
164
11

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
55
18

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
147
11

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
10

Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.
Tímea Varga, Anikó Somogyi, Gábor Barna, Barna Wichmann, Géza Nagy, Károly Rácz, László Selmeci, Gábor Firneisz. Pathol Oncol Res 2011
39
23

The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. Basic Clin Pharmacol Toxicol 2009
35
25

Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes.
J E Foley, M Ligueros-Saylan, Y-L He, J J Holst, C F Deacon, B E Dunning, A Leone-Jones, T Yu, D E Kelley. Horm Metab Res 2008
33
27



Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
Bertram Bengsch, Bianca Seigel, Tobias Flecken, Julia Wolanski, Hubert E Blum, Robert Thimme. J Immunol 2012
101
10

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingvay. J Investig Med 2013
35
25

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
65
13


Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
12

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Jill Hamilton, Elizabeth Cummings, Vera Zdravkovic, Diane Finegood, Denis Daneman. Diabetes Care 2003
106
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.